NR3C2 and Hypertension: In experimental models of hypertension, treatment with the mineralocorticoid receptor (MR) blocker spironolactone was able to reduce cerebral and renal vascular lesions, cardiac hypertrophy, inflammation, and extracellular matrix synthesis [16].